Back to Research

Organization profile

FimmCyte

FimmCyte is a Swiss biotechnology organization developing first-in-class, non-hormonal immunotherapies to treat the root causes of chronic fibro-inflammatory diseases. Its lead candidate, FMC2, utilizes a precision-based approach to eliminate diseased tissue and promote organ regeneration in women suffering from endometriosis.

Basel, SwitzerlandFounded 2023

Overview

1. Executive Summary (Confidence: High)

FimmCyte is a clinical-stage ready biotechnology spin-off from the University of Zurich (UZH) and University Hospital Zurich (USZ), founded in 2022.1 The organization is pioneering a "Blue Ocean" in women's health by moving beyond traditional symptom management toward disease-modifying therapies for endometriosis and broader fibro-inflammatory conditions.[2] Its core innovation is a proprietary antibody platform based on the "Deplete. Reprogram. Regenerate" principle, which targets specific proteins overexpressed in diseased cells to reverse fibrosis.[4] In early 2026, FimmCyte secured a landmark strategic collaboration and option-to-license agreement with Gedeon Richter, a global leader in women's health, to accelerate its lead candidate, FMC2, into human clinical trials.[2] With over $7 million in total funding and a lean, high-expertise team, FimmCyte is positioned as a critical innovator at the intersection of women's health and the longevity ecosystem's focus on targeted fibrosis reversal.[7]

This is an extract of the full organization profile. To access the full company profile, .

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.